BRPI0410714A - derivados de quinazolina - Google Patents

derivados de quinazolina

Info

Publication number
BRPI0410714A
BRPI0410714A BRPI0410714-4A BRPI0410714A BRPI0410714A BR PI0410714 A BRPI0410714 A BR PI0410714A BR PI0410714 A BRPI0410714 A BR PI0410714A BR PI0410714 A BRPI0410714 A BR PI0410714A
Authority
BR
Brazil
Prior art keywords
alkyl
independently represent
het
represent hydrogen
optionally substituted
Prior art date
Application number
BRPI0410714-4A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Timothy Pietro Suren Perera
Peter Jacobus Johan Buijnsters
Marc Willems
Gaston Stanislas Marcell Diels
Werner Constant Joha Embrechts
Peter Ten Holte
Carsten Schultz-Fademrecht
Frederik Jan Rita Rombouts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33493782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410714(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0410714A publication Critical patent/BRPI0410714A/pt
Publication of BRPI0410714B1 publication Critical patent/BRPI0410714B1/pt
Publication of BRPI0410714B8 publication Critical patent/BRPI0410714B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE QUINAZOLINA". A presente invenção se refere a compostos da fórmula: as formas de N-óxido, os sais de adição farmaceuticamente aceitáveis e as formas estereoquimicamente isoméricas do mesmo, em que: Z representa NH; Y representa -C~ 3-9~ alquila-, -C~ 2-9~ alquenila-, -C~ 3-7~alquil-CO-NH opcionalmente substituída por amino, mono - ou di(C~ 1-4~alquil)amino ou C~ 1-4~ alquilóxicarbonilamino-, -C~ 3-7~alquenil-CO-NH- opcionalmente substituído por amino, mono- ou di(C~ 1~-4~alquil)amino- ou C~ 1-4~ alquilóxicarbonilamino-, C~ 1-5~alquil-NR~ 13~-C~ 1-5~ alquila-, C~ 1-5~alquil-NR¬ 14¬-CO-C~ 1-5~ alquila-, -C~ 1-6~alquil-CO-NH-, -C~ 1-5~alquil-CO NR¬ 15¬-C~ 1-5~ alquila-, -C~ 1-3~alquil-NH-CO-Het¬ 20¬-, -C~ 1-2~alquil-CO-Het¬ 21¬CO-, -C~ 1-2~alquil-NH-CO-CR¬ 16¬R¬ 17¬-NH-, -C~ 1-2~alquiL-CO-NH-CR¬ 18¬R¬ 19¬-CO-, -C~ 1-2~alquiL-CO-Nr¬ 20¬-C~ 1-3~alquil-CO- ou -NR¬ 22¬-CO-C~ 1-3~alquil-NH-; X¬ 1¬ representa uma ligação direta, O ou -O-C~ 1-2~ alquila-; X¬ 2¬ representa uma ligação direta, -CO-C~ 1-2~ alquila-, NR¬ 12¬,-NR¬ 12¬-C~ 1-2~ alquila-, -O-N=CH- ou -C~ 1-2~ alquila-; R¬ 1¬ e R¬ 2¬ representam, cada um independentemente, hidrogênio ou halo; R¬ 3¬ representa hidrogênio; R¬ 4¬ representa hidrogênio ou C~ 1-4~ alquilóxi; R¬ 12¬ e R¬ 13¬ representam, cada um independentemente, hidrogênio OU C~ 1-4~ alquila; R¬ 14¬ e R¬ 15¬ representa hidrogênio; R¬ 16¬ e R~ 17¬ representam, cada um independentemente, hidrogênio ou C~ 1-4~ alquila; R¬ 18¬ e R¬ 19¬ representam, cada um independentemente, hidrogênio ou C~ 1-4~ alquila opcionalmente substituída por fenila ou hidróxi; R¬ 20¬ e R¬ 21¬ representam, cada um independentemente, hidrogênio OU C~ 1-4~ alquila opcionalmente substituída por C~ 1-4~ alquilóxi; Het¬ 20¬, Het¬ 21¬ e Het¬ 22¬ representam, cada um independentemente, um heterociclo selecionado do grupo consistindo de pirrolidinila, 2-pirrolidinonila ou piperidinila opcionalmente substituída por hidróxi.
BRPI0410714A 2003-05-27 2004-05-25 derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso BRPI0410714B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EPPCT/EP03/05723 2003-05-27
EP0305723 2003-05-27
EPPCT/EP03/10266 2003-09-15
EP0310266 2003-09-15
EPPCT/EP03/51061 2003-12-18
EP0351061 2003-12-18
PCT/EP2004/005621 WO2004105765A1 (en) 2003-05-27 2004-05-25 Macrocyclic quinazoline derivatives as antiproliferative agents

Publications (3)

Publication Number Publication Date
BRPI0410714A true BRPI0410714A (pt) 2006-06-13
BRPI0410714B1 BRPI0410714B1 (pt) 2019-09-24
BRPI0410714B8 BRPI0410714B8 (pt) 2021-05-25

Family

ID=33493782

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410714A BRPI0410714B8 (pt) 2003-05-27 2004-05-25 derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso

Country Status (32)

Country Link
US (4) US7648975B2 (pt)
EP (2) EP2305687A1 (pt)
JP (1) JP4887151B2 (pt)
KR (1) KR101143878B1 (pt)
CN (1) CN102718775B (pt)
AR (2) AR045687A1 (pt)
AT (1) ATE544454T1 (pt)
AU (1) AU2004243487B2 (pt)
BR (1) BRPI0410714B8 (pt)
CA (1) CA2525214C (pt)
CL (1) CL2004001267A1 (pt)
CO (1) CO5640038A2 (pt)
CY (1) CY1113002T1 (pt)
DK (1) DK1633365T3 (pt)
EA (1) EA009064B1 (pt)
ES (1) ES2381976T3 (pt)
HK (1) HK1176350A1 (pt)
HR (1) HRP20120351T1 (pt)
IL (3) IL172154A0 (pt)
IS (1) IS3030B (pt)
JO (1) JO2785B1 (pt)
MX (1) MXPA05012762A (pt)
MY (1) MY148633A (pt)
NO (1) NO334209B1 (pt)
NZ (1) NZ544154A (pt)
PA (1) PA8603801A1 (pt)
PL (1) PL1633365T3 (pt)
PT (1) PT1633365E (pt)
SI (1) SI1633365T1 (pt)
TW (3) TWI468397B (pt)
UA (1) UA84010C2 (pt)
WO (1) WO2004105765A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
KR101158440B1 (ko) * 2003-12-18 2012-07-06 얀센 파마슈티카 엔.브이. 항증식활성을 지닌 3-시아노-퀴놀린 유도체
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
ES2431843T3 (es) 2005-02-23 2013-11-28 Shionogi & Co., Ltd. Derivado de quinazolina que tiene actividad inhibidora de tirosina quinasa
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
UA92608C2 (en) * 2005-06-30 2010-11-25 Янссен Фармацевтика Н.В. Cyclic anilino - pyridinotriazines as gsk-3 inhibitors
DK2044084T3 (en) * 2006-07-13 2016-05-09 Janssen Pharmaceutica Nv MTKI-quinazoline derivatives
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
EA200970419A1 (ru) * 2006-10-27 2009-10-30 Янссен Фармацевтика Нв Микроциклические хиназолиновые производные в качестве ингибиторов vegfr3
BRPI0718021A2 (pt) * 2006-10-27 2013-11-12 Janssen Pharmaceutica Nv Uso de mtki 1 para tratar ou prevenir câncer ósseo
MX2009004437A (es) * 2006-10-27 2009-05-11 Janssen Pharmaceutica Nv El uso de un inhibidor de cinasa de multiples objetivos para el tratamiento o la prevencion del cancer cerebral.
WO2008049930A2 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv A method for profiling kinase inhibitors
WO2008087736A1 (ja) * 2007-01-19 2008-07-24 Ube Industries, Ltd. アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
TWI577680B (zh) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
NZ604708A (en) * 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
WO2013132376A1 (en) * 2012-03-06 2013-09-12 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
RU2020131276A (ru) * 2014-02-07 2020-11-03 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
IL290905B2 (en) 2014-11-16 2023-09-01 Array Biopharma Inc Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
ES2833959T3 (es) * 2016-02-29 2021-06-16 Oncodesign Sa Inhibidor del EGFR macrocíclico radiomarcado
CR20180501A (es) 2016-04-04 2019-04-05 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
SI3458456T1 (sl) 2016-05-18 2021-04-30 Loxo Oncology, Inc. Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7292299B2 (ja) * 2017-12-07 2023-06-16 アンプリックス ファーマシューティカルズ，インク． 複素環式の置換ピリジン誘導体である抗真菌薬
KR20210023984A (ko) 2018-06-25 2021-03-04 앰플릭스 파마슈티컬스, 인크. 헤테로환형 고리 및 아미노기로 치환된 피리딘 유도체
US20230159556A1 (en) * 2020-04-20 2023-05-25 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
AU2022413540A1 (en) 2021-12-16 2024-07-18 Kinnate Biopharma Inc. Inhibitors of met kinase
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (pt) * 1956-06-11
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4110333A (en) 1976-05-17 1978-08-29 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) * 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
FR2809400B1 (fr) * 2000-05-25 2004-04-09 Inst Francais Du Petrole Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB2446974B (en) * 2006-04-13 2009-01-14 Siemens Magnet Technology Ltd A solenoidal magnet structure

Also Published As

Publication number Publication date
JP2007504276A (ja) 2007-03-01
MY148633A (en) 2013-05-15
CN102718775B (zh) 2016-02-17
US9273013B2 (en) 2016-03-01
US7648975B2 (en) 2010-01-19
NO20056196L (no) 2005-12-28
CO5640038A2 (es) 2006-05-31
PT1633365E (pt) 2012-05-07
EA200501866A1 (ru) 2006-06-30
KR101143878B1 (ko) 2012-05-24
US20060247237A1 (en) 2006-11-02
TW200510431A (en) 2005-03-16
US20160207938A1 (en) 2016-07-21
EP2305687A1 (en) 2011-04-06
TWI379835B (en) 2012-12-21
HK1176350A1 (zh) 2013-07-26
PL1633365T3 (pl) 2012-07-31
PA8603801A1 (es) 2004-12-16
TWI468397B (zh) 2015-01-11
TW201245111A (en) 2012-11-16
BRPI0410714B8 (pt) 2021-05-25
UA84010C2 (en) 2008-09-10
EA009064B1 (ru) 2007-10-26
CA2525214C (en) 2012-11-27
BRPI0410714B1 (pt) 2019-09-24
IS8077A (is) 2005-10-14
EP1633365A1 (en) 2006-03-15
US20100105668A1 (en) 2010-04-29
IL233045A0 (en) 2014-07-31
MXPA05012762A (es) 2006-02-13
AR045687A1 (es) 2005-11-09
AU2004243487A1 (en) 2004-12-09
CL2004001267A1 (es) 2005-04-22
CA2525214A1 (en) 2004-12-09
CY1113002T1 (el) 2016-04-13
US20130178624A1 (en) 2013-07-11
IS3030B (is) 2021-06-15
NZ544154A (en) 2009-01-31
WO2004105765A1 (en) 2004-12-09
IL172154A0 (en) 2006-04-10
TWI468372B (zh) 2015-01-11
TW201245160A (en) 2012-11-16
JP4887151B2 (ja) 2012-02-29
CN102718775A (zh) 2012-10-10
IL233045B (en) 2018-07-31
HRP20120351T1 (hr) 2012-05-31
EP1633365B1 (en) 2012-02-08
IL233046A0 (en) 2014-07-31
AR092137A2 (es) 2015-03-25
AU2004243487B2 (en) 2009-12-03
US8394786B2 (en) 2013-03-12
SI1633365T1 (sl) 2012-06-29
NO334209B1 (no) 2014-01-13
JO2785B1 (en) 2014-03-15
ES2381976T3 (es) 2012-06-04
DK1633365T3 (da) 2012-05-14
ATE544454T1 (de) 2012-02-15
KR20060014415A (ko) 2006-02-15

Similar Documents

Publication Publication Date Title
BRPI0410714A (pt) derivados de quinazolina
MX344669B (es) Agente antiplaquetas novedoso.
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
BRPI1009637A2 (pt) composto, composição e uso de um composto
BRPI0414480A (pt) derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
WO2007126900A3 (en) Antifungal agents
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
BRPI0416853A (pt) pirazolila e imidazolila pirimidinas
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
TW200509948A (en) Prevention of urogenital infections
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
BR0315302A (pt) Benzoxazinonas substituìdas e seus usos
TW200608981A (en) Aerosol formulation for the inhalation of beta-agonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF